Colchicine Use During Breastfeeding

Herscovici, Tina; Merlob, Paul; Stahl, Bracha; Laron-Kenet, Tami; Klinger, G

doi:10.1089/bfm.2014.0086

Cited by 19 publications

(7 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Colchicine is safe during pregnancy (Skorpen 2016) and lactation (Herscovici et al 2015) based on data from the rheumatologic literature. Intravenous immunoglobulins are also considered a safe therapy during both pregnancy and lactation (Butler et al, 2014, Murase et al, 2014).…”

Section: Resultsmentioning

confidence: 99%

Autoimmune bullous diseases during pregnancy: Solving common and uncommon issues

Patsatsi

Marinović

Murrell

2019

International Journal of Women's Dermatology

View full text Add to dashboard Cite

Autoimmune bullous diseases during pregnancy pose a therapeutic challenge for medical dermatologists. There are main concerns with regard to the regimen, dose, route of administration, and potential harm to the fetus. Many therapeutic options may be safe during pregnancy despite official classifications. Furthermore, there are always questions regarding management during the lactation period. Additionally, issues exist about male and female fertility and the time of discontinuation of certain medications before conception. In this article, we present an overview of the literature based on answers to these issues to solve common and uncommon management problems that arise about a spectrum of autoimmune bullous diseases before conception, as well as during pregnancy and the lactation period.

show abstract

Section: Resultsmentioning

confidence: 99%

Autoimmune bullous diseases during pregnancy: Solving common and uncommon issues

Patsatsi

Marinović

Murrell

2019

International Journal of Women's Dermatology

View full text Add to dashboard Cite

show abstract

“…Most of the included drugs have a well‐established safety profile for use during nursing, making them a much safer option for nursing women with COVID‐19. Although colchicine was present in the milk sera of nursing mothers, its concentration was negligible, and it was safe to use during nursing (Ben‐Chetrit, 2018 ), and no side effects or long‐term effects were observed among the breastfeeding infants (Herscovici et al, 2015 ). According to the drug and lactation database in the US's national library of medicine, several reports and studies for breastfeeding mothers using prednisone or methylprednisolone showed no side effects on the infants.…”

Section: Discussionmentioning

confidence: 99%

The evidence from clinical trials on Gout medicines effect on COVID‐19: A protocol for systematic review and meta‐analysis

Bitar

Sulaiman

2022

Nursing Open

View full text Add to dashboard Cite

Aim To evaluate the available evidence from clinical trials on the efficacy of gout medicines against COVID‐19. Design Systematic review and Meta‐analysis. Methods We are systematically searching five databases [PubMed, Embase, CT.gov , ICTRP, CINAHL (EBSCO)]. We are following the PRISMA statement and the EPOC guidelines. The meta‐analysis will be conducted using Revman‐5.4.1 from Cochrane collaboration, UK. This review's protocol was also registered in PROSPERO, University of York, UK (CRD42022299718). Results In this meta‐analysis, we plan to give a conclusive overview of the available evidence on the efficacy of the medications used to manage gout in reducing COVID‐19 mortality, ICU admission, ventilation rate and hospitalization duration. If the results were positive, these drugs would greatly add to the scarce treatment options against COVID‐19. Furthermore, these drugs might provide an excellent alternative to inconvenient and expensive drugs. Additionally, most of these drugs have a well‐established safety profile for use during nursing, making them a much safer option for nursing mothers with COVID‐19.

show abstract

“…Moreover, the drug inhibits neutrophil migration to sites of inflammation, thereby serving as an anti-inflammatory [ 118 ]. Colchicine use in pregnancy and breastfeeding is controversial with an FDA class C recommendation, although recent data suggests a more lenient approach regarding its usage during pregnancy and breastfeeding [ 119 , 120 , 121 ]. Side effects include a variety of symptoms ranging from mild and frequent (e.g., gastrointestinal symptoms such as vomiting, nausea, and abdominal pain) to rare and serious (e.g., hematological dyscrasia, myalgia, neuropathy, confusion, and convulsions) [ 117 , 122 , 123 , 124 , 125 ].…”

Section: Current Prophylaxis Options For Covid-19mentioning

confidence: 99%

Potential Prophylactic Treatments for COVID-19

Ben-Zuk

Dechtman

Henn

et al. 2021

Viruses

View full text Add to dashboard Cite

The World Health Organization declared the SARS-CoV-2 outbreak a Public Health Emergency of International Concern at the end of January 2020 and a pandemic two months later. The virus primarily spreads between humans via respiratory droplets, and is the causative agent of Coronavirus Disease 2019 (COVID-19), which can vary in severity, from asymptomatic or mild disease (the vast majority of the cases) to respiratory failure, multi-organ failure, and death. Recently, several vaccines were approved for emergency use against SARS-CoV-2. However, their worldwide availability is acutely limited, and therefore, SARS-CoV-2 is still expected to cause significant morbidity and mortality in the upcoming year. Hence, additional countermeasures are needed, particularly pharmaceutical drugs that are widely accessible, safe, scalable, and affordable. In this comprehensive review, we target the prophylactic arena, focusing on small-molecule candidates. In order to consolidate a potential list of such medications, which were categorized as either antivirals, repurposed drugs, or miscellaneous, a thorough screening for relevant clinical trials was conducted. A brief molecular and/or clinical background is provided for each potential drug, rationalizing its prophylactic use as an antiviral or inflammatory modulator. Drug safety profiles are discussed, and current medical indications and research status regarding their relevance to COVID-19 are shortly reviewed. In the near future, a significant body of information regarding the effectiveness of drugs being clinically studied for COVID-19 is expected to accumulate, in addition to information regarding the efficacy of prophylactic treatments.

show abstract

Colchicine Use During Breastfeeding

Abstract: No increase in adverse long-term outcomes was found in colchicine-exposed breastfed infants. Our data support continuation of breastfeeding in women treated with colchicine.

Cited by 19 publications

References 7 publications

Autoimmune bullous diseases during pregnancy: Solving common and uncommon issues

Autoimmune bullous diseases during pregnancy: Solving common and uncommon issues

The evidence from clinical trials on Gout medicines effect on COVID‐19: A protocol for systematic review and meta‐analysis

Potential Prophylactic Treatments for COVID-19

Contact Info

Product

Resources

About